This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jung, G. Articles by Rammensee, H.-G. Search for Related Content PubMed PubMed Citation Articles by Jung, G. Articles by Rammensee, H.-G.

Target Cell-restricted Triggering of the CD95 (APO-1/Fas) Death Receptor with Bispecific Antibody Fragments¹

Department of Immunology, Institute for Cell Biology, University of Tübingen, D-72076 Tübingen, Germany [G. J., L. G-H., H-G. R.], and Tumor Immunology Program, Division of Immunogenetics, German Cancer Research Center, D-69120 Heidelberg, Germany [P. H. K.]

Like many other cell surface receptors, the CD95 (APO-1/Fas) molecule needs to be cross-linked by its physiological ligand or by immobilized or multimeric antibodies to mediate biological activity, that is, induction of apoptotic cell death. Monomeric CD95 antibodies of the IgG2a or IgG1 subtype block rather than induce apoptosis. We report here that such antibodies, hybridized to a second antibody directed against a different target antigen on the same cell, effectively induce apoptosis of the cells if the expression of the target antigen exceeds a certain threshold level. It appears that this effect is due to bicellular binding of bispecific antibodies resulting in mutual cross-linking of the CD95 death receptor and the target antigen. Using bispecific reagents, it may therefore be possible to restrict the activation of death receptors to a given target site, e.g., a tumor. In general terms, our findings illustrate a principle according to which the triggering of a cell surface receptor may be confined to a given target cell using bispecific reagents with target X cell surface receptor specificity.

This article has been cited by other articles:

				T. Herrmann, L. Grosse-Hovest, T. Otz, P. H. Krammer, H.-G. Rammensee, and G. Jung Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95 Cancer Res., February 15, 2008; 68(4): 1221 - 1227. [Abstract] [Full Text] [PDF]